Poxel SA

Poxel SA

Poxel SA

Overview
Date Founded

2009

Headquarters

259/261, avenue Jean Jaurès,Lyon, Rhone-Alpes 69007

Type of Company

Public

Employees (Worldwide)

11 - 50

Industries

Pharmaceuticals
IT Consulting & Services
Medical Support Services
Biotechnology

Company Description

Poxel SA is a pharmaceutical company, which engages in development of molecules for the potential treatment of type 2 diabetes. Its products include Imeglimin-US/EU, Imeglimin-Japan/Asia, and PXL770. The company was founded by Sébastien Bolze, Sophie Hallakou-Bozec, Pascale Fouqueray-Grellier, Pascale Malgouyres and Thomas Kuhn on March 6, 2009 and is headquartered in Lyon, France.

Contact Data
Trying to get in touch with decision makers at Poxel SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer, Co-Founder

Co-Founder

Co-Founder

Chief Financial Officer

Chief Scientific Officer

Chief Legal Officer

Executive Vice President, Business Development & President, US Operations

Investor Relations & Communication Director

Senior Vice President, Investor Relations & Public Relations

Board of Directors

Former Senior Executive Vice President & Chief Administrative Officer at Rite Aid Corp.

Chief Executive Officer, Co-Founder at Poxel SA

Venture Partner, Life Sciences at Andera Partners SCA

Chief Executive Officer, Chief Financial Officer, Director & Chief Accounting Officer at CorMedix, Inc.

Former Deputy Chief Executive Officer & Chief Financial Officer at BIOASTER

Managing Director, Life Science Group at Hercules Capital

President & Chief Executive Officer at Cosmo Public Relations Corp.

Former Senior Vice President-Business Development & Corporate Licensing at Merck & Co., Inc.

Paths to Poxel SA
Potential Connections via
Relationship Science
You
Poxel SA
Recent Transactions
Details Hidden

Poxel SA issued . EUR Ordinary Shares

Transaction Advisors
Underwriter

Advised onPoxel SA issued . EUR Ordinary Shares

Auditor

Advised onPoxel SA issued . EUR Ordinary Shares

Underwriter

Advised onPoxel SA issued . EUR Ordinary Shares

Advisors & Consultants
Advisor

Senior Vice President, Munich at MacDougall Advisors, Inc.

Advisor

Professional at Newcap - France

Advisor

Media Relations Contact at Hume Brophy

Clients

Roivant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company was founded by Vivek Ramaswamy on August 18, 2016 and is headquartered in Basel, Switzerland.

Sumitomo Dainippon Pharma Co., Ltd. engages in manufacture, sale, import, and export of pharmaceutical products. It operates through the Pharmaceutical Business and Other Business segments. The Pharmaceutical Business segment manufactures and sells generic and prescription drugs in Japan, North America, China, and other overseas countries. The Other Business segment division includes food ingredients, additives, chemical products, veterinary drugs, and diagnostic reagents. The company was founded on May 14, 1897 and is headquartered in Osaka, Japan.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

Key Stats and Financials As of 2018
Market Capitalization
$242M
Total Enterprise Value
$77.4M
Earnings Per Share
$0.54
Revenue
$74.6M
Net Profit
$13.5M
EBITDA
$9.05M
Total Equity
$55.7M
Total Debt
$14.2M
EBITDAMargin
12.13%
Enterprise Value Sales
1.04x
TEVNet Income
5.72x
Enterprise Value EBITDAOperating
8.55x
Debt TEV
0.18x
Three Year Compounded Annual Growth Rate Of Revenue
977.4%
Investors
Details Hidden

Co-Founder at Poxel SA

Details Hidden

Chief Executive Officer, Co-Founder at Poxel SA

Details Hidden

Former Professional at Procter & Gamble Co.

Suppliers
Merck KGaA Hospitals & Patient Services | Darmstadt, HE

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, and Performance Materials. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility. The Life Science sector provides scientists with laboratory materials, technologies, and services. The Performance Materials sector offers specialty chemicals and materials for demanding applications. The firm offers pharma and biopharma manufacturing, pharmaceutical research, pharma quality control, and government and academic research services. The company was founded by Friedrich Jacob Merck in 1668 and is headquartered in Darmstadt, Germany.

Competitors
Allergan Plc Pharmaceuticals - Dublin, DU

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1984 and is headquartered in Dublin, Ireland.

Intercept Pharmaceuticals, Inc. Pharmaceuticals - NEW YORK, NY

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Genfit SA Pharmaceuticals - Loos, NP

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Poxel SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Poxel SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Poxel SA.